$1.73
1.14% yesterday
Nasdaq, Dec 30, 10:16 pm CET
ISIN
US8776191061
Symbol
TSHA
Sector
Industry

Taysha Gene Therapies Inc Target price 2024 - Analyst rating & recommendation

Taysha Gene Therapies Inc Classifications & Recommendation:

Buy
100%

Taysha Gene Therapies Inc Price Target

Target Price $6.59
Price $1.73
Potential
Number of Estimates 11
11 Analysts have issued a price target Taysha Gene Therapies Inc 2025 . The average Taysha Gene Therapies Inc target price is $6.59. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 11 Analysts recommend Taysha Gene Therapies Inc to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Taysha Gene Therapies Inc stock has an average upside potential 2025 of . Most analysts recommend the Taysha Gene Therapies Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 15.45 8.25
518.00% 46.63%
EBITDA Margin -453.07% -1,126.21%
90.83% 148.57%
Net Margin -1,273.41% -878.18%
95.89% 31.04%

12 Analysts have issued a sales forecast Taysha Gene Therapies Inc 2024 . The average Taysha Gene Therapies Inc sales estimate is

$8.2m
Unlock
. This is
16.88% lower
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$15.0m 51.21%
Unlock
, the lowest is
$6.3m 36.49%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $15.5m 518.00%
2024
$8.2m 46.63%
Unlock
2025
$4.8m 41.42%
Unlock
2026
$32.0m 563.28%
Unlock
2027
$54.5m 70.23%
Unlock
2028
$154m 181.55%
Unlock

2 Analysts have issued an Taysha Gene Therapies Inc EBITDA forecast 2024. The average Taysha Gene Therapies Inc EBITDA estimate is

$-92.9m
Unlock
. This is
14.36% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-92.1m 13.42%
Unlock
, the lowest is
$-93.6m 15.30%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-70.0m 43.34%
2024
$-92.9m 32.66%
Unlock
2025
$-95.4m 2.68%
Unlock
2026
$-27.1m 71.53%
Unlock

EBITDA Margin

2023 -453.07% 90.83%
2024
-1,126.21% 148.57%
Unlock
2025
-1,974.05% 75.28%
Unlock
2026
-84.73% 95.71%
Unlock

3 Taysha Gene Therapies Inc Analysts have issued a net profit forecast 2024. The average Taysha Gene Therapies Inc net profit estimate is

$-72.4m
Unlock
. This is
1,077.74% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-69.7m 1,033.34%
Unlock
, the lowest is
$-75.8m 1,133.37%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-197m 74.60%
2024
$-72.4m 63.20%
Unlock
2025
$-71.7m 0.94%
Unlock
2026
$-81.0m 12.85%
Unlock
2027
$-62.5m 22.78%
Unlock
2028
$-13.3m 78.69%
Unlock

Net Margin

2023 -1,273.41% 95.89%
2024
-878.18% 31.04%
Unlock
2025
-1,485.02% 69.10%
Unlock
2026
-252.68% 82.98%
Unlock
2027
-114.61% 54.64%
Unlock
2028
-8.68% 92.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -0.96 -0.35
74.60% 63.54%
P/E negative
EV/Sales 31.90

3 Analysts have issued a Taysha Gene Therapies Inc forecast for earnings per share. The average Taysha Gene Therapies Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-0.35
Unlock
. This is
1,066.67% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-0.34 1,033.33%
Unlock
, the lowest is
$-0.37 1,133.33%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-0.96 74.60%
2024
$-0.35 63.54%
Unlock
2025
$-0.35 0.00%
Unlock
2026
$-0.40 14.29%
Unlock
2027
$-0.31 22.50%
Unlock
2028
$-0.07 77.42%
Unlock

P/E ratio

Current -51.62 8,093.65%
2024
-4.95 90.41%
Unlock
2025
-5.00 1.01%
Unlock
2026
-4.43 11.40%
Unlock
2027
-5.74 29.57%
Unlock
2028
-26.92 368.99%
Unlock

Based on analysts' sales estimates for 2024, the Taysha Gene Therapies Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

31.90
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
43.50
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 26.52 90.65%
2024
31.90 20.29%
Unlock
2025
54.46 70.71%
Unlock
2026
8.21 84.92%
Unlock
2027
4.82 41.25%
Unlock
2028
1.71 64.48%
Unlock

P/S ratio

Current 36.15 70.25%
2024
43.50 20.31%
Unlock
2025
74.25 70.71%
Unlock
2026
11.19 84.92%
Unlock
2027
6.58 41.26%
Unlock
2028
2.34 64.48%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today